Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens : Experience From the Amyloidosis Program of Calgary
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 23(2023), 10 vom: 31. Okt., Seite e331-e334 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lewis, Ellen [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
69G8BD63PP |
|---|
| Anmerkungen: |
Date Completed 25.09.2023 Date Revised 27.09.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2023.07.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360324126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360324126 | ||
| 003 | DE-627 | ||
| 005 | 20231226082757.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2023.07.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1201.xml |
| 035 | |a (DE-627)NLM360324126 | ||
| 035 | |a (NLM)37532664 | ||
| 035 | |a (PII)S2152-2650(23)00213-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lewis, Ellen |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens |b Experience From the Amyloidosis Program of Calgary |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2023 | ||
| 500 | |a Date Revised 27.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Bortezomib |2 NLM | |
| 650 | 7 | |a 69G8BD63PP |2 NLM | |
| 650 | 7 | |a Boronic Acids |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a McCulloch, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Mahe, Etienne |e verfasserin |4 aut | |
| 700 | 1 | |a Bahlis, Nizar |e verfasserin |4 aut | |
| 700 | 1 | |a Neri, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Tay, Jason |e verfasserin |4 aut | |
| 700 | 1 | |a Duggan, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez-Zepeda, Victor H |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 23(2023), 10 vom: 31. Okt., Seite e331-e334 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:10 |g day:31 |g month:10 |g pages:e331-e334 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2023.07.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 10 |b 31 |c 10 |h e331-e334 | ||